NCT03215095 - RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

February 6, 2023

Study Completion Date

July 31, 2026

Conditions

Thyroid Cancer

Interventions

DRUG

Durvalumab (Medi4736)

durvalumab 1500 mg IV every 4 weeks

RADIATION

Radioiodine (RAI)

100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering Commack, Commack

Memorial Sloan Kettering Basking Ridge, Basking Ridge

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale